You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中生製藥(1177.HK)高開4.17% 聯營科興新冠疫苗獲批附條件上市
格隆匯 02-08 09:22
格隆匯2月8日丨中生製藥(1177.HK)高開4.17%報7.75港元,盤前成交312萬港元,最新市值1462億港元。公司最新公吿稱,聯營公司科興中維研製的新型肺炎疫苗“克爾來福”已獲國家藥監局附條件批准註冊申請。公司指,在國內獲批附條件上市,標誌著克爾來福的臨牀研究以及在各個國家和地區的註冊和應用取得了又一重大進展。另外,集團開發的治療2型糖尿病藥物“恩格列淨片”(商品名:塞菲可)(規格:10mg及25mg)已獲中國國家藥品監督管理局頒發藥品註冊證書,且視同通過仿製藥質量和療效一致性評價。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account